国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

桑迪亞Sundia MediTech
桑迪亞醫(yī)藥技術(shù) （上海）有限責(zé)任公司，是由王曉川博士領(lǐng)銜的一批來(lái)自全球制藥行業(yè)的資深科研和管理精英于2004年創(chuàng)立的外包服務(wù) (CRO) 公司，以上海為基地向全球制藥企業(yè)和生化公司提供優(yōu)秀、高效的“一站式”新藥研發(fā)和生產(chǎn)服務(wù)。

2008年，桑迪亞公司以928％的財(cái)務(wù)增長(zhǎng)率榮膺“德勤亞太地區(qū)高科技、高成長(zhǎng)500強(qiáng)”第52名，“德勤中國(guó)高科技、高成長(zhǎng)50強(qiáng)”第16名，并連續(xù)兩年被頂尖風(fēng)險(xiǎn)投資商評(píng)為“中國(guó)最有投資價(jià)值的50家公司”之一。同時(shí)，桑迪亞還榮獲了國(guó)家“高新技術(shù)企業(yè)”、“上海重點(diǎn)服務(wù)外包企業(yè)”、“浦東新區(qū)企業(yè)技術(shù)開(kāi)發(fā)機(jī)構(gòu)”、“2009中國(guó)100強(qiáng)成長(zhǎng)型服務(wù)外包企業(yè)”等稱(chēng)號(hào)。

桑迪亞的新藥研發(fā)外包服務(wù)幾乎涵蓋了新藥研發(fā)的大部分關(guān)鍵環(huán)節(jié)，具體包括：藥物分子設(shè)計(jì)，篩選，優(yōu)化，合成，化學(xué)工藝研究與放大、化學(xué)分析測(cè)試、藥物制劑研究、分子診斷服務(wù)、藥理、藥效、藥代、安全性評(píng)價(jià)服務(wù)和符合美國(guó)cGMP規(guī)范的原料藥（High Potency API）和劑型的規(guī)模化生產(chǎn)等，集實(shí)驗(yàn)室研發(fā)和cGMP生產(chǎn)于一體。

桑迪亞利用自行建立的新藥研發(fā)服務(wù)平臺(tái)，在過(guò)去5年多的時(shí)間內(nèi)，已與來(lái)自國(guó)內(nèi)外的80多家制藥公司進(jìn)行了全面的研發(fā)合作，為合作伙伴發(fā)現(xiàn)了8個(gè)不同的候選藥物，其中有數(shù)個(gè)已進(jìn)入臨床前研究階段，有一個(gè)為合作伙伴申報(bào)的國(guó)家“一類(lèi)”創(chuàng)新藥物，獲得了中國(guó)國(guó)家食品藥品監(jiān)督管理局（SFDA）的I期臨床批文。

2009年2月9日，張江集團(tuán)和桑迪亞公司簽約共同建設(shè)“張江新藥孵化平臺(tái)”，在國(guó)內(nèi)首次采用 IP+CRO+VC（即知識(shí)產(chǎn)權(quán)、研發(fā)外包服務(wù)、風(fēng)險(xiǎn)投資相結(jié)合）的全新產(chǎn)業(yè)化模式直接孵化新藥，這將打破國(guó)內(nèi)新藥研發(fā)領(lǐng)域長(zhǎng)期偏重于重復(fù)硬件建設(shè)而不出成果的困局, 能使我國(guó)的新藥研發(fā)快速進(jìn)入到一個(gè)全新的階段。

成立7年來(lái)，桑迪亞公司規(guī)模不斷擴(kuò)大，實(shí)驗(yàn)室面積從最初的500平方米發(fā)展到如今的15,000平方米，科研、生產(chǎn)設(shè)施一流。目前，公司共有科研人員約600人，博士碩士比例約 90%，其中海歸高端人才比例約10% 。

Founded by a group of veterans from the US biopharmaceutical industry in 2004, Sundia MediTech Company Ltd. is now a leading Shanghai-based CRO company providing drug discovery and development services worldwide. In 2007, Sundia successfully merged with United PharmaTech and formed an alliance with HD Biosciences. With our technical expertise and excellent research facilities, we offer broad and integrated chemical synthesis (custom synthesis, library design and synthesis), medicinal chemistry (hit generation, lead optimization, and preclinical development), biological (early hit screening, assay development, in vitro and in vivo pharmacology, in vitro and in vivo DMPK), new technology platforms (molecular diagnostics and PBSDD and nanotechnology), and pharmaceutical development (process research and development, API manufacture, pre-formulation and formulation, analytical and QA/QC, CMC and regulatory submission) services.

Since its founding in 2004, the company's CRO service business has been growing at an amazing rate. It was consecutively named as one of the top 50 most valuable companies for investment in China in 2007 and 2008. In 2008, with its 928% revenue growth, Sundia ranked #52 in the Deloitte Technology Fast 500 Asia Pacific list and #16 in the Fast 50 China list. Our expansion through partnerships has been driven by growing demand from our clients. In the past 5 years, Sundia has successfully established collaborations with over 85 client companies in North America, Europe, and Japan.

For Sundia, our professional leadership is an important asset. Our management team is made up of scientists with advanced degrees or training and who have extensive working/management experience in North America. Our team has rich experience in organic synthesis, medicinal chemistry, process chemistry, biology, business management, and law. Our research team comprises over 600 scientists, among which 90% have a Ph.D. or a MS; and 10% a BS.